SCHEMBL17830726

SCHEMBL17830726

O=C(Cn1c(=O)oc2cc(Cl)ccc21)OCc1ccc(F)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 6/20 0.55
ALDH1A1 P00352 3/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
GAA P10253 1/20 0.52
PKM P14618 1/20 0.52
MAPT P10636 2/20 0.48
USP2 O75604 1/20 0.47
TP53 P04637 3/20 0.46
LMNA P02545 2/20 0.46
POLB P06746 4/20 0.44
CYP3A4 P08684 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PIK3CB P42338 1/20 0.44
ALPG P10696 1/20 0.43
RECQL P46063 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17830724 0.93 IDO1 (0.51) IDO1ALDH1A1KMT2AMAPTUSP2
SCHEMBL17830722 0.89 RECQL (0.55) ALDH1A1KMT2AMEN1GAAPKM
SCHEMBL17830715 0.89 PIK3CB (0.54) IDO1ALDH1A1KMT2AMEN1MAPT
SCHEMBL17830727 0.88 IDO1 (0.55) IDO1ALDH1A1KMT2AMEN1GAA
SCHEMBL17830728 0.88 ALDH1A1 (0.45) IDO1ALDH1A1KMT2AMEN1GAA
SCHEMBL17830721 0.87 TP53 (0.59) ALDH1A1KMT2AMEN1MAPTUSP2
SCHEMBL17830732 0.87 USP2 (0.47) IDO1ALDH1A1KMT2AMEN1MAPT
SCHEMBL17830725 0.85 POLB (0.52) IDO1ALDH1A1KMT2AMEN1MAPT
SCHEMBL17830734 0.85 IDO1 (0.52) IDO1ALDH1A1KMT2AMEN1MAPT
SCHEMBL17830736 0.83 MIF (0.52) IDO1ALDH1A1KMT2AMAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A IDO1 1644/4885ALDH1A1 4832/4885KMT2A 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.